Ketamine Metabolites: Norketamine and Hydroxynorketamine

What Are Norketamine and Hydroxynorketamine?

Norketamine and hydroxynorketamine (HNK) are the two main byproducts your liver produces as it breaks down ketamine. Norketamine forms first and retains some of ketamine's activity at the NMDA receptor, a glutamate receptor in the brain that ketamine blocks to produce its dissociative and antidepressant effects. HNK forms next, as the liver further processes norketamine, and one specific form of it, (2R,6R)-HNK, has become a focal point of ketamine research because animal studies suggest it may produce antidepressant-like effects through a mechanism separate from NMDA receptor blockade. Neither metabolite is an approved medication on its own; they matter because they help explain how ketamine works in the body and why the route you take it by can change your experience.

How Your Body Metabolizes Ketamine

Ketamine is metabolized primarily in the liver by two cytochrome P450 enzymes, CYP3A4 and CYP2B6, which are proteins that break down many medications into forms the body can eliminate. This process, called N-demethylation, strips a methyl group from ketamine to create norketamine. The liver then continues working on norketamine, adding a hydroxyl group through a second enzymatic step to produce hydroxynorketamine, which exists in several structural variants, the most studied being (2R,6R)-HNK and (2S,6S)-HNK.

How much norketamine and HNK your body produces, and how quickly, depends heavily on route of administration. Ketamine given intravenously (IV) or intramuscularly (IM) enters the bloodstream directly, so a larger share of the dose reaches the brain as unchanged ketamine before the liver metabolizes it. Oral and sublingual ketamine, by contrast, pass through the liver more extensively before reaching general circulation, a process called first-pass metabolism, which produces a higher ratio of norketamine relative to ketamine. For background on how these routes compare more broadly, see the complete guide to ketamine.

Norketamine: The First Metabolite

Norketamine is the direct product of ketamine metabolism and is itself pharmacologically active, meaning it produces measurable effects in the body rather than simply being an inert waste product. Pharmacology research describes norketamine as a weaker NMDA receptor antagonist than ketamine, it still blocks the receptor, but less effectively at comparable concentrations. Because norketamine has a longer elimination half-life than ketamine, it can remain detectable in blood and urine after ketamine itself has largely cleared, which is one reason norketamine is often used as a marker in drug testing.

Norketamine's contribution to ketamine's clinical effects is thought to be modest at typical IV or IM doses, where ketamine itself dominates. That contribution likely grows with routes that produce more first-pass metabolism, such as oral or sublingual dosing, where norketamine exposure relative to ketamine is higher.

Hydroxynorketamine (HNK) and the Antidepressant Research Question

Hydroxynorketamine became a major focus in ketamine research after a 2016 study published in Nature by researchers at the National Institute of Mental Health (NIMH), an agency within the U.S. National Institutes of Health that funds and conducts mental health research. The study, led by Zanos and colleagues, reported that (2R,6R)-HNK produced antidepressant-like effects in mice without directly blocking NMDA receptors, and without the dissociative-like behaviors or reward-related responses researchers associated with ketamine itself in that animal model (Zanos et al., Nature, 2016).

According to the study authors, the effect appeared linked to activation of AMPA receptors, a different type of glutamate receptor involved in synaptic signaling and plasticity, the brain's capacity to strengthen or reorganize neural connections, a process also connected to BDNF (brain-derived neurotrophic factor) signaling that researchers believe plays a role in ketamine's rapid-acting antidepressant effects. This finding mattered because it suggested a version of ketamine's benefit might be achievable without the NMDA receptor blockade responsible for dissociation, raising the possibility of a future medication with fewer perceptual side effects.

That said, this remains preclinical, animal-model evidence. Follow-up studies in the years since have produced mixed replication results, and (2R,6R)-HNK has not been developed into an FDA-approved medication for depression in humans. Readers evaluating claims about ketamine metabolites should treat this as an active, unsettled area of mechanism research rather than a proven treatment pathway, the guide on how to read ketamine depression research studies walks through how to weigh animal studies against human clinical trial evidence.

Why Metabolites Matter If You're Researching Ketamine

Understanding norketamine and HNK helps explain two things a person comparing treatment options often wants to know: why different routes of ketamine feel different, and why researchers are still investigating exactly how ketamine relieves depressive symptoms. Ketamine's clinical effects likely involve a combination of the parent drug's NMDA receptor blockade and downstream effects from its metabolites, rather than any single mechanism acting alone.

This is also a reminder that ketamine research is still evolving. The FDA's 2019 approval of esketamine nasal spray for treatment-resistant depression was based on clinical trials of esketamine itself, not on norketamine or HNK (FDA press announcement, March 2019). If you're weighing ketamine or esketamine as a treatment option, metabolite research is useful background, but your decision should rest on the approved indication, the supervision requirements, and your clinician's assessment of your situation, not on preliminary mechanism findings. Review safety and side effect information and the FAQ on how ketamine works for broader context, and talk with a licensed clinician about what applies to you. This article is educational and not a substitute for medical advice.